Showing 1871-1880 of 5696 results for "".
- Tarsus Launches Demodex Blepharitis Treatment Xdemvyhttps://modernod.com/news/tarsis-launches-demodex-blepharitis-treatment-xdemvy/2481792/Tarsus Pharmaceuticals announced that Xdemvy (lotilaner ophthalmic solution 0.25%) is now available at pharmacies nationwide for prescription. The FDA approved Xdemvy on July 24, 2023, for the treatment of Demodex blepharitis. “We are delighted that w
- Kodiak Discontinues Further Development of Tarcocimab After Phase 3 Trial Datahttps://modernod.com/news/kodiak-discontinues-further-development-of-tarcocimab-after-phase-3-trial-data/2481748/Kodiak Sciences has announed it discontinuing further development of tarcocimab tedromer, a novel antibody biopolymer conjugate, being evaluated for wet AMD and DME. The decision comes after the GLEAM and GLIMMER studies failed to meet their primary efficacy endpoints. Th
- FDA Accepts DORC’s Orphan-Drug Designation Application for Trypan Blue and Brilliant Blue Ghttps://modernod.com/news/fda-accepts-dorcs-orphan-drug-designation-application-for-trypan-blue-and-brilliant-blue-g/2481740/DORC has has received notification from the FDA that their application for orphan drug designation for a dual combination of Trypan Blue and Brilliant Blue G ophthalmic solutions has been granted. DORC's MembraneBlue-Dual ILM and ERM stain has been used in more than 500,00
- Harrow Acquires US and Canadian Commercial Rights to Dry Eye Drug Vevye from Novaliqhttps://modernod.com/news/harrow-acquires-us-and-canadian-commercial-rights-to-vevye-cyclosporine-ophthalmic-solution-01-from-novaliq/2481734/Harrow has entered the prescription dry eye disease treatment business as it announced a deal to acquire the US and Canadian commercial rights to Vevye (cyclosporine ophthalmic solution 0.1%) from Novaliq. Under terms of the deal, Harrow will make an initi
- OcuTerra Completes Enrollment in Phase 2 DR:EAM Trial of Topically Delivered OTT166 in Adults with Diabetic Retinopathyhttps://modernod.com/news/ocuterra-completes-enrollment-in-phase-2-dream-trial-of-topically-delivered-ott166-in-adults-with-diabetic-retinopathy/2481732/OcuTerra Therapeutics announced full enrollment in the company’s phase 2 DR:EAM (Diabetic Retinopathy: Early Active Management) clinical trial evaluating topically delivered OTT166 eye drops in adult patients with moderately severe to severe nonproliferative diabeti
- Smartlens Closes $6.1 Million Series A Financing to Advance miLens Devicehttps://modernod.com/news/smartlens-closes-61-million-series-a-financing-to-advance-milens/2481727/Smartlens has closed an oversubscribed $6.1 million Series A equity financing round to advance regulatory clearance for miLens, a novel, electronics-free, soft contact lens for monitoring diurnal IOP. The miLens device is an electronics free soft contact lens that uses mi
- Study Uncovers Novel Synaptic Intricacies Inside the Retinahttps://modernod.com/news/study-uncovers-novel-synaptic-intricacies-inside-the-retina/2481687/A Northwestern Medicine study has uncovered novel cellular mechanisms within the retina, findings that researchers say could help advance the development of targeted therapeutics for diseases and conditions impacting vision. The findings were
- Senju Pharmaceutical and Novaliq Enter Into License Agreement For NOV03 For the Treatment of Dry Eye Disease in Japanhttps://modernod.com/news/senju-pharmaceutical-and-novaliq-enter-into-license-agreement-for-nov03-for-the-treatment-of-dry-eye-disease-in-japan/2481671/Senju Pharmaceutical and Novaliq have enteed into a license agreement for NOV03 (perfluorohexyloctane ophthalmic solution) for the treatment of dry eye disease in Japan. Financial terms of the deal were not disclosed. Senju Pharmaceutical acquires the rights in Japa
- EyePoint Pharmaceuticals Completes Enrollment in Phase 2 PAVIA Clinical Trial of EYP-1901 in Non-Proliferative Diabetic Retinopathyhttps://modernod.com/news/eyepoint-pharmaceuticals-completes-enrollment-in-phase-2-pavia-clinical-trial-of-eyp-1901-in-non-proliferative-diabetic-retinopathy/2481648/EyePoint Pharmaceuticals announced it has completed enrollment in the phase 2 PAVIA clinical trial evaluating EYP-1901 as a potential 9-month treatment for moderate to severe non-proliferative diabetic retinopathy (NPDR). “We are delighted to report the completion of enrollment in
- FDA Approves Bausch + Lomb and Novaliq's Miebo for the Treatment of the Signs and Symptoms of Dry Eye Diseasehttps://modernod.com/news/bausch-lomb-and-novaliq-announce-fda-approval-of-miebotm-perfluorohexyloctane-ophthalmic-solution-for-the-treatment-of-the-signs-and-symptoms-of-dry-eye-disease/2481625/Bausch + Lomb announced on Thursday that the FDA has approved Miebo (perfluorohexyloctane ophthalmic solution; formerly known as NOV03) for the treatment of the signs and symptoms of dry eye disease (DED). The comapnies say Miebo is the first and only FDA-approved treatment fo